Khan Najat
Insider CIK 2020969 · RXRX Chief R&D Commercial Officer, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2026-09-08 | 2026-09-10 | 22,408 | $3.52 | $78.9K | 2,072,890 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2026-09-08 | 2026-09-10 | 22,408 | $3.52 | $78.8K | 2,072,890 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2026-08-17 | 2026-08-18 | 80,498 | $3.16 | $254.4K | 2,095,298 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2026-08-17 | 2026-08-18 | 80,498 | $3.16 | $254.4K | 2,095,298 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2026-06-05 | 2026-06-05 | 23,588 | $3.58 | $84.4K | 2,175,796 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2026-05-15 | 2026-05-19 | 62,701 | $3.04 | $190.6K | 2,199,384 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2026-03-09 | 2026-03-11 | 28,298 | $3.35 | $94.8K | 2,262,085 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2026-02-17 | 2026-02-19 | 14,280 | $3.49 | $49.8K | 2,290,383 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2026-02-06 | 2026-02-10 | 10,364 | $3.98 | $41.2K | 2,304,663 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2026-02-06 | 2026-02-10 | 1,673,546 | — | $0 | 2,284,681 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2026-02-06 | 2026-02-10 | 30,346 | — | $0 | 2,315,027 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2025-12-22 | 2025-12-29 | 124,403 | $4.41 | $548.6K | 611,135 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2025-11-17 | 2025-11-19 | 17,584 | $4.14 | $72.8K | 735,538 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2025-11-05 | 2025-11-06 | 169,851 | — | $0 | 169,851 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2025-11-05 | 2025-11-06 | 84,925 | — | $0 | 753,122 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2025-08-18 | 2025-08-19 | 36,599 | $5.52 | $202.0K | 668,197 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2025-08-15 | 2025-08-19 | 3,789 | $5.64 | $21.4K | 704,796 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2025-05-15 | 2025-05-19 | 3,796 | $4.25 | $16.1K | 708,585 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2025-02-03 | 2025-02-05 | 420,226 | — | $0 | 420,226 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2025-02-03 | 2025-02-05 | 8,049 | — | $0 | 715,134 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2025-02-03 | 2025-02-05 | 210,113 | — | $0 | 707,085 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2025-02-03 | 2025-02-05 | 2,753 | $7.25 | $20.0K | 712,381 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2024-08-01 | 2024-08-05 | 993,944 | — | $0 | 993,944 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2024-08-01 | 2024-08-05 | 496,972 | — | $0 | 496,972 | SEC↗ |